New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension

(E-pub Ahead of Print)

Author(s): Valentina Mercurio*, Anna Bianco, Giacomo Campi, Alessandra Cuomo, Nermin Diab, Angela Mancini, Paolo Parrella, Mario Petretta, Paul Hassoun, Domenico Bonaduce.

Journal Name: Current Medicinal Chemistry

Submit Manuscript
Submit Proposal

Abstract:

Despite recent advances in pulmonary arterial hypertension (PAH) treatment, this condition is still characterized by an extremely poor prognosis. In this review, we discuss the use of newly-approved drugs for PAH treatment with already known mechanisms of action (macitentan), innovative targets (riociguat and selexipag), and novel therapeutic approaches with initial up-front combination therapy. Secondly, we describe new potential signaling pathways and investigational drugs with promising role in the treatment of PAH.

Keywords: Pulmonary Hypertension, endothelin receptor, soluble guanylate cyclase, prostanoids, initial combination therapy, gene therapy, serotonin, inflammation, immunity, metabolism, pulmonary arterial denervation.

Rights & PermissionsPrintExport Cite as


Article Details

(E-pub Ahead of Print)
DOI: 10.2174/0929867325666180201095743
Price: $95

Article Metrics

PDF: 39